ASH 2020 | Subcutaneous mosunetuzumab in R/R B-cell lymphoma
Ian Flinn, MD, PhD, Tennessee Oncology, Nashville, TN, gives an update of an ongoing Phase I/Ib trial (NCT02500407) of mosunetuzumab (monsun), a fully humanized CD20-CD3 bispecific antibody, in relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma. Intravenous administration of the T-cell engager has previously been reported as tolerable and efficacious. Subcutaneous dosing is now being trialed to minimize the risk of cytokine release syndrome (CRS). Dose-escalation used a standard 3+3 design to test safety and efficacy. In the first 23 patients treated to date, the maximum tolerated dose has not been reached, and no patients have discontinued due to toxicity. All CRS events were grade 1 or 2, and the grade 2 events occurred at much higher doses than in the IV cohort. Early efficacy results are also encouraging. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
Disclosures
Consultancy: AbbVie, AstraZeneca, BeiGene, Genentech, Gilead Sciences, Great Point Partners, Iksuda Therapeutics, Janssen, Juno Therapeutics, Kite Pharma, MorphoSys, Nurix Therapeutics, Pharmacyclics, Roche, Seattle Genetics, Takeda, TG Therapeutics, Unum Therapeutics, Verastem, Yingli Pharmaceuticals
Research Grants: AbbVie, Acerta Pharma, Agios, ArQule, AstraZeneca, BeiGene, Calithera Biosciences, Celgene, Constellation Pharmaceuticals, Curis, Forma Therapeutics, Forty Seven, Genentech, Gilead Sciences, IGM Biosciences, Incyte, Infinity Pharmaceuticals, Janssen, Juno Therapeutics, Karyopharm Therapeutics, Kite Pharma, Loxo, Merck, MorphoSys, Novartis, Pfizer, Pharmacyclics, Portola Pharmaceuticals, Rhizen Pharmaceuticals, Roche, Seattle Genetics, Takeda, Teva, TG Therapeutics, Trillium Therapeutics, Triphase Research & Development Corp., Unum Therapeutics, Verastem
All payments made to Sarah Cannon Research Institute, not to the physician.
